首页 > 最新文献

Archives of Medical Science最新文献

英文 中文
Pepsinogen I, pepsinogen II, gastrin-17, and Helicobacter pylori serological biomarkers in the diagnosis of precursor lesions of gastric cancer. 胃蛋白酶原 I、胃蛋白酶原 II、胃泌素-17 和幽门螺旋杆菌血清学生物标志物在胃癌前病变诊断中的应用。
IF 3 4区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-06-28 eCollection Date: 2024-01-01 DOI: 10.5114/aoms/189971
Josefina Yoaly Sánchez-López, Luis Carlos Díaz-Herrera, Lourdes Del Carmen Rizo-de la Torre

Introduction: Atrophic gastritis and intestinal metaplasia are precursor lesions of gastric cancer. The aim of this study was to determine the usefulness of the biomarkers pepsinogen I(PgI), pepsinogen II (PgII), gastrin-17, and H. pylori antibodies in the identification of precursor lesions.

Methods: We studied 129 patients with gastric symptoms. The biomarker status was determined using GastroPanel by means of the ELISA-technique.

Results: Biomarkers detected atrophy in 14% of the subjects, and 49.6% had positive antibodies for H. pylori. A PgI/PgII ratio < 3 was an important risk biomarker for precursor lesions in our population (OR = 9.171, 95% CI: 1.723-48.799, p = 0.009); however, biomarkers showed low accuracy with histopathological study.

Conclusions: In the Western Mexican population, precursor lesions (AG, IM) are common in adults (45%) with dyspepsia but infrequent in children (8%). H. pylori infection was detected in 41.3% of adults and 16.0% of children. Of the studied biomarkers, a PgI/PgII ratio < 3 was an important risk factor for precursor lesions such as AG or IM in our population, with an OR of 9.171 (95% CI: 1.723-48.799, p = 0.009).

简介:萎缩性胃炎和肠化生是胃癌的前兆病变:萎缩性胃炎和肠化生是胃癌的前驱病变。本研究旨在确定胃蛋白酶原 I (PgI)、胃蛋白酶原 II (PgII)、胃泌素-17 和幽门螺杆菌抗体等生物标志物在识别前驱病变中的作用:我们对 129 名有胃部症状的患者进行了研究。方法:我们对 129 名有胃部症状的患者进行了研究,通过 ELISA 技术使用 GastroPanel 对生物标志物状态进行了测定:结果:14%的受试者通过生物标志物检测到胃萎缩,49.6%的受试者幽门螺杆菌抗体呈阳性。PgI/PgII比值小于3是我们人群中前驱病变的重要风险生物标志物(OR = 9.171,95% CI:1.723-48.799,p = 0.009);然而,生物标志物与组织病理学研究的准确性较低:在墨西哥西部人群中,前驱病变(AG、IM)常见于患有消化不良的成年人(45%),但在儿童中并不常见(8%)。41.3%的成人和16.0%的儿童检测出幽门螺杆菌感染。在所研究的生物标志物中,PgI/PgII 比率小于 3 是我们人群中出现 AG 或 IM 等前驱病变的重要风险因素,OR 值为 9.171(95% CI:1.723-48.799,P = 0.009)。
{"title":"Pepsinogen I, pepsinogen II, gastrin-17, and <i>Helicobacter pylori</i> serological biomarkers in the diagnosis of precursor lesions of gastric cancer.","authors":"Josefina Yoaly Sánchez-López, Luis Carlos Díaz-Herrera, Lourdes Del Carmen Rizo-de la Torre","doi":"10.5114/aoms/189971","DOIUrl":"https://doi.org/10.5114/aoms/189971","url":null,"abstract":"<p><strong>Introduction: </strong>Atrophic gastritis and intestinal metaplasia are precursor lesions of gastric cancer. The aim of this study was to determine the usefulness of the biomarkers pepsinogen I(PgI), pepsinogen II (PgII), gastrin-17, and <i>H. pylori</i> antibodies in the identification of precursor lesions.</p><p><strong>Methods: </strong>We studied 129 patients with gastric symptoms. The biomarker status was determined using GastroPanel by means of the ELISA-technique.</p><p><strong>Results: </strong>Biomarkers detected atrophy in 14% of the subjects, and 49.6% had positive antibodies for <i>H. pylori</i>. A PgI/PgII ratio < 3 was an important risk biomarker for precursor lesions in our population (OR = 9.171, 95% CI: 1.723-48.799, <i>p</i> = 0.009); however, biomarkers showed low accuracy with histopathological study.</p><p><strong>Conclusions: </strong>In the Western Mexican population, precursor lesions (AG, IM) are common in adults (45%) with dyspepsia but infrequent in children (8%). <i>H. pylori</i> infection was detected in 41.3% of adults and 16.0% of children. Of the studied biomarkers, a PgI/PgII ratio < 3 was an important risk factor for precursor lesions such as AG or IM in our population, with an OR of 9.171 (95% CI: 1.723-48.799, <i>p</i> = 0.009).</p>","PeriodicalId":8278,"journal":{"name":"Archives of Medical Science","volume":"20 3","pages":"1016-1021"},"PeriodicalIF":3.0,"publicationDate":"2024-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11264142/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141756823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Delayed multiple arterial haemorrhage after pelvic fracture: report of a rare case. 骨盆骨折后延迟性多发性动脉出血:一例罕见病例的报告。
IF 3 4区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-06-06 eCollection Date: 2024-01-01 DOI: 10.5114/aoms/188204
Jiao Dai, Junhong He, Shan Gao, Feng Cao, Ying Ying
{"title":"Delayed multiple arterial haemorrhage after pelvic fracture: report of a rare case.","authors":"Jiao Dai, Junhong He, Shan Gao, Feng Cao, Ying Ying","doi":"10.5114/aoms/188204","DOIUrl":"https://doi.org/10.5114/aoms/188204","url":null,"abstract":"","PeriodicalId":8278,"journal":{"name":"Archives of Medical Science","volume":"20 4","pages":"1374-1377"},"PeriodicalIF":3.0,"publicationDate":"2024-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11493062/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142516256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Acute renal failure caused by Sjögren's syndrome and rheumatoid arthritis overlap syndrome. 斯约格伦综合征和类风湿性关节炎重叠综合征引起的急性肾衰竭。
IF 3 4区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-06-06 eCollection Date: 2024-01-01 DOI: 10.5114/aoms/187780
Lei Ran, Ya-Pu Zhang, Li Guo, Zhi-Min Wang, Jian-Min Zhang

Introduction: Sjögren's syndrome (SS) and rheumatoid arthritis (RA) are two chronic autoimmune diseases. To date, there have been few reports on the overlap between SS and RA in China, especially regarding correlated acute renal failure cases.

Methods: To provide a reference for our clinical peers, this article presents the case report of an elderly female patient who was diagnosed with acute renal failure caused by SS and RA overlap syndrome.

Results: We also provide a relevant analysis of SS and RA overlap syndrome treatment.

Conclusions: We also provide a relevant analysis of SS and RA overlap syndrome treatment.

导言:斯约格伦综合征(SS)和类风湿性关节炎(RA)是两种慢性自身免疫性疾病。迄今为止,国内关于SS与RA重叠的报道较少,尤其是相关的急性肾功能衰竭病例:为了给临床同行提供参考,本文报告了一名老年女性患者因SS和RA重叠综合征导致急性肾衰竭的病例:结果:我们还对SS和RA重叠综合征的治疗进行了相关分析:我们还对 SS 和 RA 重叠综合征的治疗进行了相关分析。
{"title":"Acute renal failure caused by Sjögren's syndrome and rheumatoid arthritis overlap syndrome.","authors":"Lei Ran, Ya-Pu Zhang, Li Guo, Zhi-Min Wang, Jian-Min Zhang","doi":"10.5114/aoms/187780","DOIUrl":"https://doi.org/10.5114/aoms/187780","url":null,"abstract":"<p><strong>Introduction: </strong>Sjögren's syndrome (SS) and rheumatoid arthritis (RA) are two chronic autoimmune diseases. To date, there have been few reports on the overlap between SS and RA in China, especially regarding correlated acute renal failure cases.</p><p><strong>Methods: </strong>To provide a reference for our clinical peers, this article presents the case report of an elderly female patient who was diagnosed with acute renal failure caused by SS and RA overlap syndrome.</p><p><strong>Results: </strong>We also provide a relevant analysis of SS and RA overlap syndrome treatment.</p><p><strong>Conclusions: </strong>We also provide a relevant analysis of SS and RA overlap syndrome treatment.</p>","PeriodicalId":8278,"journal":{"name":"Archives of Medical Science","volume":"20 3","pages":"1034-1037"},"PeriodicalIF":3.0,"publicationDate":"2024-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11264085/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141756805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Microsatellite instability and somatic gene variant profile in solid organ tumors.
IF 3 4区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-05-28 eCollection Date: 2024-01-01 DOI: 10.5114/aoms/185326
Ibrahim Halil Erdogdu, Seda Orenay-Boyacioglu, Olcay Boyacioglu, Nesibe Kahraman-Cetin, Habibe Guler, Merve Turan, Ibrahim Meteoglu

Introduction: Absence of mismatch repair (MMR) genes in tumor cells or errors in the replication repair process may lead to DNA-MMR deficiency and microsatellite instability (MSI) formation. Specific tumor environments where gene variations are observed are believed to be conducive to the formation of MSI. This study aimed to determine the MSI status, MMR protein expression, and somatic mutation profile in solid organ tumors.

Material and methods: In this study, the records of 192 patients with solid organ tumors who were referred to the Molecular Pathology Laboratory between January 2018 and December 2022 were reviewed retrospectively. The MSI profiles of the patients were evaluated using real-time polymerase chain reaction (PCR) and immunohistochemical (IHC) methods. Somatic variations in the patients were detected using an NGS colon cancer panel.

Results: In the IHC evaluation, 22 cases showed MMR-deficient (dMMR) or high MSI (MSI-H), and 170 cases showed MMR-proficient (pMMR) or microsatellite stable (MSS). Real-time PCR results on the 22 dMMR cases revealed that 11 cases had MSI-H and 11 cases had MSS status. Among the 170 cases with pMMR, 160 cases were found to have MSS status, while 10 cases had low MSI (MSI-L). NGS analysis revealed that the three most frequent pathogenic variants in all cases were BLM exon 7 c.1544delA, MSH3 exon 7 c.1148delA, and MLH3 exon 2 c.1755delA. MSI-H cancer patients had a higher variation burden compared to MSS cancer patients. The most frequently observed pathogenic variant in both MSI-H and MSS cancer patients was BLM exon 7 c.1544delA.

Conclusions: Our study covers not only colorectal cancer patients but also other solid tumor types, providing the first data from the Turkish population on the MSI-H/dMMR status and somatic mutation profile in the presence of this condition.

{"title":"Microsatellite instability and somatic gene variant profile in solid organ tumors.","authors":"Ibrahim Halil Erdogdu, Seda Orenay-Boyacioglu, Olcay Boyacioglu, Nesibe Kahraman-Cetin, Habibe Guler, Merve Turan, Ibrahim Meteoglu","doi":"10.5114/aoms/185326","DOIUrl":"10.5114/aoms/185326","url":null,"abstract":"<p><strong>Introduction: </strong>Absence of mismatch repair (MMR) genes in tumor cells or errors in the replication repair process may lead to DNA-MMR deficiency and microsatellite instability (MSI) formation. Specific tumor environments where gene variations are observed are believed to be conducive to the formation of MSI. This study aimed to determine the MSI status, MMR protein expression, and somatic mutation profile in solid organ tumors.</p><p><strong>Material and methods: </strong>In this study, the records of 192 patients with solid organ tumors who were referred to the Molecular Pathology Laboratory between January 2018 and December 2022 were reviewed retrospectively. The MSI profiles of the patients were evaluated using real-time polymerase chain reaction (PCR) and immunohistochemical (IHC) methods. Somatic variations in the patients were detected using an NGS colon cancer panel.</p><p><strong>Results: </strong>In the IHC evaluation, 22 cases showed MMR-deficient (dMMR) or high MSI (MSI-H), and 170 cases showed MMR-proficient (pMMR) or microsatellite stable (MSS). Real-time PCR results on the 22 dMMR cases revealed that 11 cases had MSI-H and 11 cases had MSS status. Among the 170 cases with pMMR, 160 cases were found to have MSS status, while 10 cases had low MSI (MSI-L). NGS analysis revealed that the three most frequent pathogenic variants in all cases were <i>BLM</i> exon 7 <i>c.1544delA</i>, <i>MSH3</i> exon 7 <i>c.1148delA</i>, and <i>MLH3</i> exon 2 <i>c.1755delA</i>. MSI-H cancer patients had a higher variation burden compared to MSS cancer patients. The most frequently observed pathogenic variant in both MSI-H and MSS cancer patients was <i>BLM</i> exon 7 <i>c.1544delA</i>.</p><p><strong>Conclusions: </strong>Our study covers not only colorectal cancer patients but also other solid tumor types, providing the first data from the Turkish population on the MSI-H/dMMR status and somatic mutation profile in the presence of this condition.</p>","PeriodicalId":8278,"journal":{"name":"Archives of Medical Science","volume":"20 5","pages":"1672-1679"},"PeriodicalIF":3.0,"publicationDate":"2024-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11623171/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142793998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison of the effectiveness of the helmet interface using flow meters versus the mechanical ventilator for non-invasive ventilation in patients with coronavirus disease 2019. Controlled and randomized clinical trial.
IF 3 4区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-05-28 eCollection Date: 2024-01-01 DOI: 10.5114/aoms/183947
Fernanda Dos Reis Ferreira, João Carlos Ferrari Correa, Eduardo Storopoli, Diego Restivo Faria, Karina Cassaro, Natália Feitosa da Hora, Raphael Ritti, Rafael Akira Becker, Simone Dal Corso, Ivan Peres Costa, Luciana Maria Malosá Sampaio

Introduction: This study aimed to compare the effectiveness of two methods for non-invasive mechanical ventilation in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) - using a helmet interface with a flow meter and positive end-expiratory pressure valve versus a traditional mechanical ventilator.

Material and methods: We conducted a single-center randomized clinical trial involving 100 adult SARS-CoV-2 patients in a specialized private hospital. Participants were randomly assigned to two groups: one using the helmet interface with a flow meter and positive end-expiratory pressure valve and the other employing conventional mechanical ventilation. Our study included participant selection, blood gas analysis, assessment of respiratory rate, peripheral oxygen saturation, modified Borg scale scores, and a visual analog scale.

Results: The study showed no significant difference in intubation rates between the mechanical ventilation (54.3%) and helmet interface with flow meter and positive end-expiratory pressure valve (46.8%) groups (p = 0.37). Additionally, the helmet group had a shorter average duration of use (3.4 ±1.6 days) compared to the mechanical ventilation group (4.0 ±1.9 days). The helmet group also had a shorter average hospitalization duration (15.9 ±7.9 days) compared to the mechanical ventilation group (17.1 ±9.5 days).

Conclusions: This single-center randomized clinical trial found no statistically significant differences between the two methods of non-invasive ventilation. Implications for clinical practice: using the helmet interface with the flow meter and positive end-expiratory pressure valve can simplify device installation, potentially reducing the need for intubation, making it a valuable tool for nurses and physiotherapists in daily clinical practice.

{"title":"Comparison of the effectiveness of the helmet interface using flow meters versus the mechanical ventilator for non-invasive ventilation in patients with coronavirus disease 2019. Controlled and randomized clinical trial.","authors":"Fernanda Dos Reis Ferreira, João Carlos Ferrari Correa, Eduardo Storopoli, Diego Restivo Faria, Karina Cassaro, Natália Feitosa da Hora, Raphael Ritti, Rafael Akira Becker, Simone Dal Corso, Ivan Peres Costa, Luciana Maria Malosá Sampaio","doi":"10.5114/aoms/183947","DOIUrl":"10.5114/aoms/183947","url":null,"abstract":"<p><strong>Introduction: </strong>This study aimed to compare the effectiveness of two methods for non-invasive mechanical ventilation in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) - using a helmet interface with a flow meter and positive end-expiratory pressure valve versus a traditional mechanical ventilator.</p><p><strong>Material and methods: </strong>We conducted a single-center randomized clinical trial involving 100 adult SARS-CoV-2 patients in a specialized private hospital. Participants were randomly assigned to two groups: one using the helmet interface with a flow meter and positive end-expiratory pressure valve and the other employing conventional mechanical ventilation. Our study included participant selection, blood gas analysis, assessment of respiratory rate, peripheral oxygen saturation, modified Borg scale scores, and a visual analog scale.</p><p><strong>Results: </strong>The study showed no significant difference in intubation rates between the mechanical ventilation (54.3%) and helmet interface with flow meter and positive end-expiratory pressure valve (46.8%) groups (<i>p</i> = 0.37). Additionally, the helmet group had a shorter average duration of use (3.4 ±1.6 days) compared to the mechanical ventilation group (4.0 ±1.9 days). The helmet group also had a shorter average hospitalization duration (15.9 ±7.9 days) compared to the mechanical ventilation group (17.1 ±9.5 days).</p><p><strong>Conclusions: </strong>This single-center randomized clinical trial found no statistically significant differences between the two methods of non-invasive ventilation. Implications for clinical practice: using the helmet interface with the flow meter and positive end-expiratory pressure valve can simplify device installation, potentially reducing the need for intubation, making it a valuable tool for nurses and physiotherapists in daily clinical practice.</p>","PeriodicalId":8278,"journal":{"name":"Archives of Medical Science","volume":"20 5","pages":"1538-1546"},"PeriodicalIF":3.0,"publicationDate":"2024-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11623150/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142794389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Incremental long-term benefit of drug therapies for chronic obstructive pulmonary disease in quality of life but not mortality: a network meta-analysis.
IF 3 4区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-05-28 eCollection Date: 2024-01-01 DOI: 10.5114/aoms/183025
Qiong Pan, Jiongzhou Sun, Shiyuan Gao, Zian Liu, Yiwen Huang, Yixin Lian

Introduction: The latest evidence revealed that dupilumab, an interleukin-4 (IL-4) and interleukin-13 (IL-13) blocker, significantly reduces the exacerbation risk in patients with chronic obstructive pulmonary disease (COPD). The efficacy of dupilumab compared with conventional inhaled drugs remains incompletely determined. This study aimed to investigate the comparative efficacy of dupilumab and conventional inhaled drugs in patients with stable COPD.

Material and methods: This study retrieved randomised clinical trials (RCTs) with follow-up ≥ 48 weeks on long-acting β-agonists (LABAs), long-acting muscarinic receptor antagonists (LAMAs), inhaled corticosteroids (ICSs), and dupilumab in the PubMed, EMBASE, and Cochrane Central Register of Controlled Trials databases. The information on eligible studies was extracted after the screening. The comparative efficacy of 4 drugs and their combinations in acute exacerbation and mortality was assessed using Bayesian network meta-analysis models.

Results: This network meta-analysis identified 69 eligible RCTs on 7 classes of drug therapies after stepwise screening and included 125,331 COPD patients. Compared with placebo, the 7 drug interventions significantly reduced the risk of acute exacerbation, and the reduction degree increased with the incremental use of drug classes. ICS/LABA/LAMA/dupilumab was the most effective in decreasing exacerbation risk (OR = 0.561 [95% CI: 0.387-0.810]), followed by ICS/LABA/LAMA (OR = 0.717 [95% CI: 0.626-0.817]). The 7 drug therapies were not significantly associated with a lower risk of death compared to placebo. Nevertheless, ICS/LABA/LAMA/dupilumab is the most likely to be effective in decreasing mortality.

Conclusions: The incremental use of combinations of conventional and novel drugs contributed to the long-term benefits in acute exacerbation but not death in COPD. The optimal drug combination in terms of acute COPD exacerbation was ICS/LABA/LAMA/dupilumab.

{"title":"Incremental long-term benefit of drug therapies for chronic obstructive pulmonary disease in quality of life but not mortality: a network meta-analysis.","authors":"Qiong Pan, Jiongzhou Sun, Shiyuan Gao, Zian Liu, Yiwen Huang, Yixin Lian","doi":"10.5114/aoms/183025","DOIUrl":"10.5114/aoms/183025","url":null,"abstract":"<p><strong>Introduction: </strong>The latest evidence revealed that dupilumab, an interleukin-4 (IL-4) and interleukin-13 (IL-13) blocker, significantly reduces the exacerbation risk in patients with chronic obstructive pulmonary disease (COPD). The efficacy of dupilumab compared with conventional inhaled drugs remains incompletely determined. This study aimed to investigate the comparative efficacy of dupilumab and conventional inhaled drugs in patients with stable COPD.</p><p><strong>Material and methods: </strong>This study retrieved randomised clinical trials (RCTs) with follow-up ≥ 48 weeks on long-acting β-agonists (LABAs), long-acting muscarinic receptor antagonists (LAMAs), inhaled corticosteroids (ICSs), and dupilumab in the PubMed, EMBASE, and Cochrane Central Register of Controlled Trials databases. The information on eligible studies was extracted after the screening. The comparative efficacy of 4 drugs and their combinations in acute exacerbation and mortality was assessed using Bayesian network meta-analysis models.</p><p><strong>Results: </strong>This network meta-analysis identified 69 eligible RCTs on 7 classes of drug therapies after stepwise screening and included 125,331 COPD patients. Compared with placebo, the 7 drug interventions significantly reduced the risk of acute exacerbation, and the reduction degree increased with the incremental use of drug classes. ICS/LABA/LAMA/dupilumab was the most effective in decreasing exacerbation risk (OR = 0.561 [95% CI: 0.387-0.810]), followed by ICS/LABA/LAMA (OR = 0.717 [95% CI: 0.626-0.817]). The 7 drug therapies were not significantly associated with a lower risk of death compared to placebo. Nevertheless, ICS/LABA/LAMA/dupilumab is the most likely to be effective in decreasing mortality.</p><p><strong>Conclusions: </strong>The incremental use of combinations of conventional and novel drugs contributed to the long-term benefits in acute exacerbation but not death in COPD. The optimal drug combination in terms of acute COPD exacerbation was ICS/LABA/LAMA/dupilumab.</p>","PeriodicalId":8278,"journal":{"name":"Archives of Medical Science","volume":"20 5","pages":"1586-1596"},"PeriodicalIF":3.0,"publicationDate":"2024-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11623174/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142794415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Enhancing postmenopausal osteoporosis: a study of KLF2 transcription factor secretion and PI3K-Akt signaling pathway activation by PIK3CA in bone marrow mesenchymal stem cells. 加强绝经后骨质疏松症:骨髓间充质干细胞中 KLF2 转录因子分泌和 PIK3CA 激活 PI3K-Akt 信号通路的研究。
IF 3 4区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-05-15 eCollection Date: 2024-01-01 DOI: 10.5114/aoms/171785
Wenjie Ma, Chen Li

Introduction: Mesenchymal stem cells can develop into osteoblasts, making them a promising cell-based osteoporosis treatment. Despite their therapeutic potential, their molecular processes are little known. Bioinformatics and experimental analysis were used to determine the molecular processes of bone marrow mesenchymal stem cell (BMSC) therapy for postmenopausal osteoporosis (PMO).

Material and methods: We used weighted gene co-expression network analysis (WGCNA) to isolate core gene sets from two GEO microarray datasets (GSE7158 and GSE56815). GeneCards found PMO-related genes. GO, KEGG, Lasso regression, and ROC curve analysis refined our candidate genes. Using the GSE105145 dataset, we evaluated KLF2 expression in BMSCs and examined the link between KLF2 and PIK3CA using Pearson correlation analysis. We created a protein-protein interaction network of essential genes involved in osteoblast differentiation and validated the functional roles of KLF2 and PIK3CA in BMSC osteoblast differentiation in vitro.

Results: We created 6 co-expression modules from 10 419 differentially expressed genes (DEGs). PIK3CA, the key gene in the PI3K-Akt pathway, was among 197 PMO-associated DEGs. KLF2 also induced PIK3CA transcription in PMO. BMSCs also expressed elevated KLF2. BMSC osteoblast differentiation involved the PI3K-Akt pathway. In vitro, KLF2 increased PIK3CA transcription and activated the PI3K-Akt pathway to differentiate BMSCs into osteoblasts.

Conclusions: BMSCs release KLF2, which stimulates the PIK3CA-dependent PI3K-Akt pathway to treat PMO. Our findings illuminates the involvement of KLF2 and the PI3K-Akt pathway in BMSC osteoblast development, which may lead to better PMO treatments.

引言间充质干细胞可发育成成骨细胞,是一种很有前景的骨质疏松症治疗细胞。尽管它们具有治疗潜力,但其分子过程却鲜为人知。我们利用生物信息学和实验分析来确定骨髓间充质干细胞(BMSC)治疗绝经后骨质疏松症(PMO)的分子过程:我们使用加权基因共表达网络分析(WGCNA)从两个GEO微阵列数据集(GSE7158和GSE56815)中分离出核心基因组。GeneCards 发现了与 PMO 相关的基因。GO、KEGG、Lasso 回归和 ROC 曲线分析完善了我们的候选基因。利用 GSE105145 数据集,我们评估了 KLF2 在 BMSCs 中的表达情况,并利用皮尔逊相关分析检验了 KLF2 与 PIK3CA 之间的联系。我们创建了参与成骨细胞分化的重要基因的蛋白-蛋白相互作用网络,并在体外验证了 KLF2 和 PIK3CA 在 BMSC 成骨细胞分化中的功能作用:我们从10 419个差异表达基因(DEGs)中创建了6个共表达模块。PIK3CA是PI3K-Akt通路中的关键基因,是197个与PMO相关的DEGs之一。KLF2也诱导了PMO中PIK3CA的转录。BMSCs也表达了升高的KLF2。BMSC成骨细胞的分化涉及PI3K-Akt通路。在体外,KLF2增加了PIK3CA的转录并激活了PI3K-Akt通路,使BMSCs分化成成骨细胞:结论:BMSCs 释放 KLF2,刺激 PIK3CA 依赖性 PI3K-Akt 通路,从而治疗 PMO。我们的研究结果阐明了KLF2和PI3K-Akt通路在BMSC成骨细胞发育过程中的参与,这可能有助于更好地治疗PMO。
{"title":"Enhancing postmenopausal osteoporosis: a study of KLF2 transcription factor secretion and PI3K-Akt signaling pathway activation by PIK3CA in bone marrow mesenchymal stem cells.","authors":"Wenjie Ma, Chen Li","doi":"10.5114/aoms/171785","DOIUrl":"https://doi.org/10.5114/aoms/171785","url":null,"abstract":"<p><strong>Introduction: </strong>Mesenchymal stem cells can develop into osteoblasts, making them a promising cell-based osteoporosis treatment. Despite their therapeutic potential, their molecular processes are little known. Bioinformatics and experimental analysis were used to determine the molecular processes of bone marrow mesenchymal stem cell (BMSC) therapy for postmenopausal osteoporosis (PMO).</p><p><strong>Material and methods: </strong>We used weighted gene co-expression network analysis (WGCNA) to isolate core gene sets from two GEO microarray datasets (GSE7158 and GSE56815). GeneCards found PMO-related genes. GO, KEGG, Lasso regression, and ROC curve analysis refined our candidate genes. Using the GSE105145 dataset, we evaluated KLF2 expression in BMSCs and examined the link between KLF2 and PIK3CA using Pearson correlation analysis. We created a protein-protein interaction network of essential genes involved in osteoblast differentiation and validated the functional roles of KLF2 and PIK3CA in BMSC osteoblast differentiation <i>in vitro.</i></p><p><strong>Results: </strong>We created 6 co-expression modules from 10 419 differentially expressed genes (DEGs). PIK3CA, the key gene in the PI3K-Akt pathway, was among 197 PMO-associated DEGs. KLF2 also induced PIK3CA transcription in PMO. BMSCs also expressed elevated KLF2. BMSC osteoblast differentiation involved the PI3K-Akt pathway. <i>In vitro</i>, KLF2 increased PIK3CA transcription and activated the PI3K-Akt pathway to differentiate BMSCs into osteoblasts.</p><p><strong>Conclusions: </strong>BMSCs release KLF2, which stimulates the PIK3CA-dependent PI3K-Akt pathway to treat PMO. Our findings illuminates the involvement of KLF2 and the PI3K-Akt pathway in BMSC osteoblast development, which may lead to better PMO treatments.</p>","PeriodicalId":8278,"journal":{"name":"Archives of Medical Science","volume":"20 3","pages":"918-937"},"PeriodicalIF":3.0,"publicationDate":"2024-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11264107/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141756818","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Predictive value of the BDH2-MN2 nomogram model for prognosis at 3 months after receiving intravenous thrombolysis in patients with acute ischemic stroke. 急性缺血性脑卒中患者接受静脉溶栓治疗后 3 个月预后的 BDH2-MN2 提名图模型预测价值。
IF 3 4区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-05-13 eCollection Date: 2024-01-01 DOI: 10.5114/aoms/176740
Yinglei Li, Ning Li, Lingyun Xi, Litao Li

Introduction: The present study focused on developing a nomogram model to predict the 3-month survival of patients with acute ischemic stroke (AIS) receiving intravenous thrombolysis with tissue plasminogen activator (tPA).

Material and methods: A total of 709 patients were enrolled in the present study, including 496 patients in the training set and 213 patients in the validation set. All data were statistically analyzed using R software. We applied LASSO regression analysis to construct nomograms by screening statistically significant predictors from all variables.The model discrimination was evaluated based on the area under the receiver operating characteristic curve (AUC-ROC).

Results: LASSO regression analysis was conducted for all variables, which revealed BNP, DNT, HCY, HDL, MHR, NHR and post-thrombolysis NIHSS as independent predictors of adverse outcomes at 3 months after intravenous thrombolysis. Accordingly, these seven factors were incorporated in the nominated BDH2-MN2 nomogram. The resulting AUC-ROC values determined for the training and validation sets were 0.937 (95% CI: 0.822-0.954) and 0.898 (95% CI: 0.748-0.921), respectively.

Conclusions: A robust BDH2-MN2 (BNP, DNT, HCY, HDL, MHR, NHR and post-thrombolysis NIHSS) nomogram model was successfully developed and validated. The developed nomogram enables prediction of adverse outcomes of individual AIS patients receiving intravenous thrombolysis with alteplase for 3 months.

简介本研究的重点是建立一个提名图模型,用于预测接受组织血浆酶原激活剂(tPA)静脉溶栓治疗的急性缺血性卒中(AIS)患者的 3 个月生存率:本研究共招募了 709 名患者,其中 496 名患者为训练集,213 名患者为验证集。所有数据均使用 R 软件进行统计分析。我们应用 LASSO 回归分析,从所有变量中筛选出具有统计学意义的预测因子,构建提名图。根据接收者操作特征曲线下面积(AUC-ROC)评估模型的区分度:对所有变量进行了LASSO回归分析,结果显示BNP、DNT、HCY、HDL、MHR、NHR和溶栓后NIHSS是静脉溶栓后3个月不良预后的独立预测因子。因此,这七个因素被纳入了提名的 BDH2-MN2 提名图中。训练集和验证集得出的AUC-ROC值分别为0.937(95% CI:0.822-0.954)和0.898(95% CI:0.748-0.921):成功开发并验证了一个稳健的 BDH2-MN2 (BNP、DNT、HCY、HDL、MHR、NHR 和溶栓后 NIHSS)提名图模型。所开发的提名图能够预测接受阿替普酶静脉溶栓治疗 3 个月的 AIS 患者的不良预后。
{"title":"Predictive value of the BDH2-MN2 nomogram model for prognosis at 3 months after receiving intravenous thrombolysis in patients with acute ischemic stroke.","authors":"Yinglei Li, Ning Li, Lingyun Xi, Litao Li","doi":"10.5114/aoms/176740","DOIUrl":"https://doi.org/10.5114/aoms/176740","url":null,"abstract":"<p><strong>Introduction: </strong>The present study focused on developing a nomogram model to predict the 3-month survival of patients with acute ischemic stroke (AIS) receiving intravenous thrombolysis with tissue plasminogen activator (tPA).</p><p><strong>Material and methods: </strong>A total of 709 patients were enrolled in the present study, including 496 patients in the training set and 213 patients in the validation set. All data were statistically analyzed using R software. We applied LASSO regression analysis to construct nomograms by screening statistically significant predictors from all variables.The model discrimination was evaluated based on the area under the receiver operating characteristic curve (AUC-ROC).</p><p><strong>Results: </strong>LASSO regression analysis was conducted for all variables, which revealed BNP, DNT, HCY, HDL, MHR, NHR and post-thrombolysis NIHSS as independent predictors of adverse outcomes at 3 months after intravenous thrombolysis. Accordingly, these seven factors were incorporated in the nominated BDH2-MN2 nomogram. The resulting AUC-ROC values determined for the training and validation sets were 0.937 (95% CI: 0.822-0.954) and 0.898 (95% CI: 0.748-0.921), respectively.</p><p><strong>Conclusions: </strong>A robust BDH2-MN2 (BNP, DNT, HCY, HDL, MHR, NHR and post-thrombolysis NIHSS) nomogram model was successfully developed and validated. The developed nomogram enables prediction of adverse outcomes of individual AIS patients receiving intravenous thrombolysis with alteplase for 3 months.</p>","PeriodicalId":8278,"journal":{"name":"Archives of Medical Science","volume":"20 4","pages":"1143-1152"},"PeriodicalIF":3.0,"publicationDate":"2024-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11493034/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142493644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nomogram for predicting reflux esophagitis with routine metabolic parameters: a retrospective study. 利用常规代谢参数预测反流性食管炎的提名图:一项回顾性研究。
IF 3 4区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-04-30 eCollection Date: 2024-01-01 DOI: 10.5114/aoms/175536
Tao He, Xiaoyu Sun, Zhijun Duan

Introduction: The prevalence of reflux esophagitis (RE) is relatively high around the world. We investigated routine metabolic parameters for associations with RE prevalence and severity, creating a user-friendly RE prediction nomogram.

Material and methods: We included 10,881 individuals who had upper gastrointestinal endoscopy at a hospital. We employed univariate and multivariate logistic regression for independent risk factors related to RE prevalence, and conducted ordinal logistic regression for independent prognostic factors of RE severity. Subsequently, a nomogram was constructed using multivariate logistic regression analysis, and its performance was assessed through the utilization of receiver operating characteristic (ROC) curves, calibration curves, decision curve analysis (DCA), and clinical impact curve (CIC) analysis.

Results: In this study, 43.8% (4769 individuals) had confirmed RE. Multivariate analysis identified BMI, age, alcohol use, diabetes, Helicobacter pylori, systolic blood pressure (SBP), diastolic blood pressure (DBP), glucose, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides (TG), total cholesterol (TC), albumin, uric acid (UA), fT3, and fT4 as independent RE risk factors (p < 0.05). The personalized nomogram used 17 factors to predict RE, with an AUC of 0.921 (95% CI: 0.916-0.926), specificity 84.02%, sensitivity 84.86%, and accuracy 84.39%, reflecting excellent discrimination. Calibration, decision, and CIC analyses affirmed the model's high predictive accuracy and clinical utility. Additionally, ordinal logistic regression linked hypertension, diabetes, HDL-C, LDL-C, TG, and TC to RE severity.

Conclusions: Our study highlights the association between the routine metabolic parameters and RE prevalence and severity. The nomogram may be of great value for the prediction of RE prevalence.

导言:全世界反流性食管炎(RE)的发病率相对较高。我们研究了常规代谢参数与反流性食管炎发病率和严重程度的关系,并创建了一个方便用户使用的反流性食管炎预测提名图:我们纳入了在一家医院接受上消化道内窥镜检查的 10881 名患者。我们采用单变量和多变量逻辑回归分析了与RE患病率相关的独立风险因素,并对RE严重程度的独立预后因素进行了序数逻辑回归分析。随后,利用多变量逻辑回归分析构建了一个提名图,并通过接收者操作特征曲线(ROC)、校准曲线、决策曲线分析(DCA)和临床影响曲线分析(CIC)对其性能进行了评估:在这项研究中,43.8%(4 769 人)确诊为 RE。多变量分析确定体重指数(BMI)、年龄、饮酒、糖尿病、幽门螺旋杆菌、收缩压(SBP)、舒张压(DBP)、葡萄糖、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、甘油三酯(TG)、总胆固醇(TC)、白蛋白、尿酸(UA)、fT3 和 fT4 为独立的 RE 危险因素(P < 0.05).个性化提名图使用 17 个因素预测 RE,AUC 为 0.921(95% CI:0.916-0.926),特异性为 84.02%,灵敏度为 84.86%,准确性为 84.39%,反映出极佳的辨别能力。校准、决策和 CIC 分析证实了该模型的高预测准确性和临床实用性。此外,序数逻辑回归将高血压、糖尿病、高密度脂蛋白胆固醇、低密度脂蛋白胆固醇、总胆固醇和总胆固醇与 RE 的严重程度联系起来:我们的研究强调了常规代谢参数与 RE 患病率和严重程度之间的关联。结论:我们的研究强调了常规代谢指标与 RE 患病率和严重程度之间的关联,该提名图可能对预测 RE 患病率具有重要价值。
{"title":"Nomogram for predicting reflux esophagitis with routine metabolic parameters: a retrospective study.","authors":"Tao He, Xiaoyu Sun, Zhijun Duan","doi":"10.5114/aoms/175536","DOIUrl":"https://doi.org/10.5114/aoms/175536","url":null,"abstract":"<p><strong>Introduction: </strong>The prevalence of reflux esophagitis (RE) is relatively high around the world. We investigated routine metabolic parameters for associations with RE prevalence and severity, creating a user-friendly RE prediction nomogram.</p><p><strong>Material and methods: </strong>We included 10,881 individuals who had upper gastrointestinal endoscopy at a hospital. We employed univariate and multivariate logistic regression for independent risk factors related to RE prevalence, and conducted ordinal logistic regression for independent prognostic factors of RE severity. Subsequently, a nomogram was constructed using multivariate logistic regression analysis, and its performance was assessed through the utilization of receiver operating characteristic (ROC) curves, calibration curves, decision curve analysis (DCA), and clinical impact curve (CIC) analysis.</p><p><strong>Results: </strong>In this study, 43.8% (4769 individuals) had confirmed RE. Multivariate analysis identified BMI, age, alcohol use, diabetes, <i>Helicobacter pylori</i>, systolic blood pressure (SBP), diastolic blood pressure (DBP), glucose, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides (TG), total cholesterol (TC), albumin, uric acid (UA), fT3, and fT4 as independent RE risk factors (<i>p</i> < 0.05). The personalized nomogram used 17 factors to predict RE, with an AUC of 0.921 (95% CI: 0.916-0.926), specificity 84.02%, sensitivity 84.86%, and accuracy 84.39%, reflecting excellent discrimination. Calibration, decision, and CIC analyses affirmed the model's high predictive accuracy and clinical utility. Additionally, ordinal logistic regression linked hypertension, diabetes, HDL-C, LDL-C, TG, and TC to RE severity.</p><p><strong>Conclusions: </strong>Our study highlights the association between the routine metabolic parameters and RE prevalence and severity. The nomogram may be of great value for the prediction of RE prevalence.</p>","PeriodicalId":8278,"journal":{"name":"Archives of Medical Science","volume":"20 4","pages":"1089-1100"},"PeriodicalIF":3.0,"publicationDate":"2024-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11493045/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142493642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Role of nutrition and healthy lifestyle, for individuals in primary prevention: recent data, gaps in evidence and future directions.
IF 3 4区 医学 Q1 MEDICINE, GENERAL & INTERNAL Pub Date : 2024-04-30 eCollection Date: 2024-01-01 DOI: 10.5114/aoms/187841
Theodora Metsovitis, Marco Bernardi, Eric Bruckert, Federica Fogacci, Arrigo Cicero, Sebastian Garcia-Zamora, Luigi Spadafora, Denis Angoulvant, Giuseppe Biondi-Zoccai, Pierre Sabouret

All recent guidelines on cardiovascular prevention have highlighted the role of a healthy diet and lifestyle advocating an holistic approach to reduce the cardiovascular burden among the population. Despite these efforts, registries have reported that only a minority of healthcare professionals provide advice on diet and lifestyle, and, in most cases, counseling is suboptimal for several reasons. Cardiovascular benefits linked to lifestyle and nutrition seem to be underestimated by many patients and doctors. This overview aims to summarize well-established benefits related to lifestyle and nutrition, discuss the current debates in this field in order to improve awareness among the medical community and promote better implementation of non-pharmaceutical measures to prevent the occurrence of atherothrombotic events, by reducing cardiovascular risk factors such as hypertension, diabetes, dyslipidemia, and obesity.

{"title":"Role of nutrition and healthy lifestyle, for individuals in primary prevention: recent data, gaps in evidence and future directions.","authors":"Theodora Metsovitis, Marco Bernardi, Eric Bruckert, Federica Fogacci, Arrigo Cicero, Sebastian Garcia-Zamora, Luigi Spadafora, Denis Angoulvant, Giuseppe Biondi-Zoccai, Pierre Sabouret","doi":"10.5114/aoms/187841","DOIUrl":"10.5114/aoms/187841","url":null,"abstract":"<p><p>All recent guidelines on cardiovascular prevention have highlighted the role of a healthy diet and lifestyle advocating an holistic approach to reduce the cardiovascular burden among the population. Despite these efforts, registries have reported that only a minority of healthcare professionals provide advice on diet and lifestyle, and, in most cases, counseling is suboptimal for several reasons. Cardiovascular benefits linked to lifestyle and nutrition seem to be underestimated by many patients and doctors. This overview aims to summarize well-established benefits related to lifestyle and nutrition, discuss the current debates in this field in order to improve awareness among the medical community and promote better implementation of non-pharmaceutical measures to prevent the occurrence of atherothrombotic events, by reducing cardiovascular risk factors such as hypertension, diabetes, dyslipidemia, and obesity.</p>","PeriodicalId":8278,"journal":{"name":"Archives of Medical Science","volume":"20 5","pages":"1385-1399"},"PeriodicalIF":3.0,"publicationDate":"2024-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11623160/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142793915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Archives of Medical Science
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1